AU1667795A - Pharmaceutical piperazine compounds - Google Patents

Pharmaceutical piperazine compounds

Info

Publication number
AU1667795A
AU1667795A AU16677/95A AU1667795A AU1667795A AU 1667795 A AU1667795 A AU 1667795A AU 16677/95 A AU16677/95 A AU 16677/95A AU 1667795 A AU1667795 A AU 1667795A AU 1667795 A AU1667795 A AU 1667795A
Authority
AU
Australia
Prior art keywords
piperazine compounds
pharmaceutical
pharmaceutical piperazine
compounds
piperazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU16677/95A
Other versions
AU693159B2 (en
Inventor
Stephen James Brocchini
Julie Elizabeth Brumwell
Justin Stephen Bryans
Adrian John Folkes
Christopher John Latham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenova Ltd
Original Assignee
Xenova Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenova Ltd filed Critical Xenova Ltd
Publication of AU1667795A publication Critical patent/AU1667795A/en
Application granted granted Critical
Publication of AU693159B2 publication Critical patent/AU693159B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU16677/95A 1994-02-14 1995-02-14 Pharmaceutical piperazine compounds Ceased AU693159B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9402807 1994-02-14
GB9402807A GB9402807D0 (en) 1994-02-14 1994-02-14 Pharmaceutical compounds
PCT/GB1995/000302 WO1995021832A1 (en) 1994-02-14 1995-02-14 Pharmaceutical piperazine compounds

Publications (2)

Publication Number Publication Date
AU1667795A true AU1667795A (en) 1995-08-29
AU693159B2 AU693159B2 (en) 1998-06-25

Family

ID=10750355

Family Applications (1)

Application Number Title Priority Date Filing Date
AU16677/95A Ceased AU693159B2 (en) 1994-02-14 1995-02-14 Pharmaceutical piperazine compounds

Country Status (8)

Country Link
EP (1) EP0745070A1 (en)
JP (1) JPH09509157A (en)
AU (1) AU693159B2 (en)
CA (1) CA2182877A1 (en)
GB (2) GB9402807D0 (en)
IL (1) IL112624A0 (en)
WO (1) WO1995021832A1 (en)
ZA (1) ZA951180B (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112627A0 (en) * 1994-02-14 1995-05-26 Xenova Ltd Diketopiperazines, their preparation and pharmaceutical or veterinary compositions containing them
GB9426090D0 (en) * 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
HUP0003608A3 (en) 1997-05-03 2001-06-28 Smithkline Beecham Plc Tetrahydroisoquinoline derivatives, process for producing them and pharmaceutical compositions containing them
DE69817460T2 (en) 1997-06-09 2004-06-09 Hitachi, Ltd. Image sequence decoding method
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
CO5140073A1 (en) 1998-10-08 2002-03-22 Smithkline Beecham Plc DERIVATIVES OF 2,3,4,5-TETRAHIDRO-1H-3-BENZAPINA
EP1264831A4 (en) * 2000-01-18 2005-11-23 Nereus Pharmaceuticals Inc Cell division inhibitors and process for producing the same
KR100852965B1 (en) * 2000-05-09 2008-08-19 애드파르마 인코포레이티드 Piperazinedione compounds
AU9450501A (en) * 2000-05-09 2001-12-24 Adpharma Inc Piperazinedione compounds
US7288545B2 (en) 2000-05-09 2007-10-30 Angiorx Corporation Piperazinedione compounds
GB2372740A (en) * 2001-01-17 2002-09-04 Xenova Ltd Diketopiperazines
TW591020B (en) * 2001-06-20 2004-06-11 Wyeth Corp 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US7064201B2 (en) 2002-08-02 2006-06-20 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
CA2553630A1 (en) * 2004-02-04 2005-08-25 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
WO2005115990A1 (en) * 2004-05-26 2005-12-08 Eisai R & D Management Co., Ltd. Cinnamide compound
CA2580119A1 (en) 2004-10-26 2006-05-04 Eisai R & D Management Co., Ltd. Amorphous object of cinnamide compound
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
EP2072498A4 (en) 2006-10-12 2012-07-18 Inst Med Molecular Design Inc N-phenyloxamidic acid derivative
WO2008044729A1 (en) 2006-10-12 2008-04-17 Institute Of Medicinal Molecular Design. Inc. Carboxylic acid derivative
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
TW200848054A (en) 2007-02-28 2008-12-16 Eisai R&D Man Co Ltd Two cyclic oxomorpholine derivatives
BRPI0815773A2 (en) 2007-08-31 2019-09-24 Eisai R&D Man Co Ltd compound and medicine.
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
AU2008314979A1 (en) 2007-10-23 2009-04-30 Institute Of Medicinal Molecular Design, Inc. Inhibitor of PAI-1 production
BRPI0906348A2 (en) 2008-04-11 2019-07-16 Inst Of Medicinal Molecular Designer Inc compound represented by formula (1), pharmaceutical composition; pai-1 inhibitor and prevention drug for prevention and / or therapeutic treatment of disease caused by the manifestation of pai-1 or increased action of pai-1
CN102119153A (en) * 2008-08-13 2011-07-06 巴斯夫欧洲公司 Method for preparation of piperazindione derivates
ES2701069T3 (en) * 2012-12-21 2019-02-20 Epizyme Inc PRMT5 inhibitors and their uses
CN105272968B (en) * 2014-06-10 2018-03-13 首都医科大学 The diketone of (3S, 6R) 3,6 disubstituted piperazine 2,5, it is prepared and application
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
WO2016034673A1 (en) 2014-09-03 2016-03-10 Ctxt Pty Ltd Tetrahydroisoquinoline derived prmt5-inhibitors
WO2016034671A1 (en) 2014-09-03 2016-03-10 Ctxt Pty Ltd Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors
RU2736045C2 (en) 2015-03-06 2020-11-11 Бейондспринг Фармасьютикалс, Инк. Method of treating cancer associated with a ras mutation
CA2978679A1 (en) 2015-03-06 2016-09-15 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
PE20180528A1 (en) 2015-07-13 2018-03-19 Beyondspring Pharmaceuticals Inc PLINABULIN COMPOSITIONS
AU2017217426B2 (en) 2016-02-08 2022-12-01 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
GB201604022D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604029D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604020D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604031D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604027D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604030D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
CN109475524A (en) 2016-06-06 2019-03-15 万春药业公司 For reducing the composition and method of neutrophilic granulocytopenia
CN106565686B (en) * 2016-10-11 2019-03-01 深圳海王医药科技研究院有限公司 Antitubulin
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20190109479A (en) 2017-02-01 2019-09-25 비욘드스프링 파마수티컬스, 인코포레이티드. How to reduce neutropenia
EP3684767B1 (en) 2017-09-22 2024-04-24 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
FI3697785T3 (en) 2017-10-18 2023-04-03 Jubilant Epipad LLC Imidazo-pyridine compounds as pad inhibitors
CN111386265A (en) 2017-11-06 2020-07-07 朱比连特普罗德尔有限责任公司 Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
IL274762B2 (en) 2017-11-24 2023-10-01 Jubilant Episcribe Llc Novel heterocyclic compounds as prmt5 inhibitors
EP3743074A4 (en) 2018-01-24 2021-12-15 Beyondspring Pharmaceuticals Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
KR20200131845A (en) 2018-03-13 2020-11-24 주빌런트 프로델 엘엘씨 Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
CN116400068B (en) * 2023-02-13 2023-09-22 泉州圣源警用侦察设备有限公司 Reagent for revealing potential biological trace containing DNA and revealing method

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE621862C (en) * 1932-07-01 1935-11-14 Guenther Schiemann Dr Process for the preparation of condensation products of nucleus fluorinated aryl aldehydes
GB9217331D0 (en) * 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
JPH08247357A (en) * 1995-03-13 1996-09-27 Zexel Corp Flange joint and forming method thereof

Also Published As

Publication number Publication date
JPH09509157A (en) 1997-09-16
IL112624A0 (en) 1995-05-26
GB2286395B (en) 1998-08-26
GB2286395A (en) 1995-08-16
ZA951180B (en) 1996-08-14
AU693159B2 (en) 1998-06-25
CA2182877A1 (en) 1995-08-17
WO1995021832A1 (en) 1995-08-17
GB9402807D0 (en) 1994-04-06
GB9502874D0 (en) 1995-04-05
EP0745070A1 (en) 1996-12-04

Similar Documents

Publication Publication Date Title
AU1667795A (en) Pharmaceutical piperazine compounds
AU2533495A (en) Pharmaceutical diketopiperazine compounds
GB9423542D0 (en) Pharmaceutical compounds
AU1667595A (en) Pharmaceutical piperazine compounds
AU1588495A (en) Pharmaceutical piperazin compounds
GB9426224D0 (en) Pharmaceutical compounds
ZA957607B (en) Pharmaceutical compounds
AU4330097A (en) Pharmaceutical compounds
GB9417102D0 (en) Pharmaceutical compounds
AU4169897A (en) Pharmaceutical compounds
ZA9510903B (en) Pharmaceutical compounds
GB9426080D0 (en) Pharmaceutical compounds
AU1667695A (en) Pharmaceutical piperazine compounds
AUPO008396A0 (en) New piperazine compounds
GB2324301B (en) Pharmaceutical Piperazine Compounds
AU6607094A (en) Pharmaceutical compounds
GB9414457D0 (en) Pharmaceutical compounds
GB9425040D0 (en) Pharmaceutical compounds
ZA951176B (en) Pharmaceutical compounds
GB9402889D0 (en) Pharmaceutical compounds
GB9426092D0 (en) Pharmaceutical compounds
GB9426074D0 (en) Pharmaceutical compounds
SG32533A1 (en) Pharmaceutical compounds
SG32534A1 (en) Pharmaceutical compounds
GB9406052D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired